



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



SCIENTIFIC LETTER

Assessment of plasma endocan for the prediction of mortality in COVID-19 patients undergoing veno-venous ECMO: A pilot study

Evaluación del endocan para la predicción de la mortalidad en pacientes COVID-19 sometidos a ECMO veno-venosa: un estudio piloto

Dear Editor:

Patients with severe COVID-19 related acute respiratory distress syndrome (ARDS) may benefit from V-V ECMO support. However, this technique remains associated with frequent complications and high mortality.¹ The early identification of patients with V-V ECMO who are likely to survive on ICU discharge therefore seems of major interest.

Endocan is a circulating proteoglycan secreted by the pulmonary vasculature under inflammatory conditions such as ARDS.² Recent data suggest that monitoring of blood endocan during 1st week following intensive care unit (ICU) admission may correlate with the severity of ARDS in Covid-19.³

Thus, we aimed in this study to assess whether plasma endocan measurements performed on the day of V-V ECMO implantation (D0) and repeated seven days later (D7) may be effective in predicting mortality on ICU discharge.

This study was conducted in a 50-bed mixed ICU, from October 2020 to June 2021. We included all consecutive COVID-19 patients undergoing V-V ECMO implantation and with available results of plasma endocan measured on day of ECMO implantation.

Endocan was measured weekly on EDTA plasma in the central laboratory of our hospital using the ENDOMARK H1 ELISA kit (Biothelis, France) in COVID-19 patients admitted in our ICU as part as the routine assessment of prognosis in ARDS,⁴⁻⁶ along with CRP and fibrinogen. This research was examined by our local IRB, and approved under the number HP 22/01. Because of the retrospective observational design, written informed consent was not required.

Patients' characteristics were obtained at D0. We also retrospectively collected values on D0 and D7 for plasma endocan (endocan_{D0} and endocan_{D7}), CRP (CRP_{D0} and CRP_{D7}) and fibrinogen (fibrinogen_{D0} and fibrinogen_{D7}).

Variations between D0 and D7 were respectively calculated for endocan (endocan_{D0-D7}), CRP (CRP_{D0-D7}) and fibrinogen (fibrinogen_{D0-D7}) as following: (value on D7 – value on D0)/value on D0.

Categorical variables were expressed as numbers (percentages) and compared using Fisher's exact test, given small sample sizes. Skewed continuous variables were presented as median (interquartile range) and compared using Mann-Whitney U test.

Decision tree based on CART algorithm was generated using the *rpart* R package with default settings, using endocan_{D0}, endocan_{D7}, endocan_{D0-D7}, CRP_{D0}, CRP_{D7}, CRP_{D0-D7}, fibrinogen_{D0}, fibrinogen_{D7} and fibrinogen_{D0-D7} as covariates.

All statistical tests were two-tailed, and *p* values <0.05 were considered statistically significant. Statistical analysis was performed using R version 3.6 (R foundation for statistical analysis, Austria).

Eleven patients undergoing V-V ECMO implantation for COVID-19 related ARDS were included in this study, of whom 5 (45%) were discharged alive from ICU. All patients underwent invasive mechanical ventilation (MV) during their stay in ICU, although invasive MV was initiated right before ECMO implantation and maintained less than 24 h for 2 patients from the survivors group.

Compared to survivors, non-survivors had higher endocan_{D7} (median [IQR] = 12.9 [6.1; 19] ng/ml vs 4.3 [3.9; 5.6] ng/ml; *p* = 0.017), and greater increase in endocan_{D0-D7} (median [IQR] = +208 [-1; +612] % vs -49 [-65; +52]%; *p* = 0.03). Conversely, no difference was found between non-survivors and survivors for endocan_{D0} (median [IQR] = 4.7 [3; 5.7] ng/ml vs 7.9 [3.8; 12.2] ng/ml; *p* = 0.25), CRP_{D0} (median [IQR] = 94 [68; 200] mg/l vs 118 [26; 150] mg/l; *p* = 0.66), CRP_{D7} (median [IQR] = 68 [50; 77] mg/l vs 39 [35; 123] mg/l; *p* = 0.41), CRP_{D0-D7} (median [IQR] = -17 [-72; -5] % vs 4 [-75; +484]%; *p* = 0.54), fibrinogen_{D0} (median [IQR] = 7.1 [4.9; 8.1] g/l vs 6.1 [3.9; 6.8] g/l; *p* = 0.33), fibrinogen_{D7} (median [IQR] = 5.1 [4.3; 5.6] g/l vs 4.6 [2.7; 5.1] g/l; *p* = 0.23), and fibrinogen_{D0-D7} (median [IQR] = -26 [-43; +9] % vs -28 [-50; +15]%; *p* = 1) (Table 1).

According to a decision tree based on a CART algorithm, a 2-nodes model combining endocan_{D0-D7} with static value of endocan_{D0} was able to correctly identify all survivors and non-survivors. Indeed, according to this decision tree, 3/3 patients with endocan_{D0-D7} < -40% survived, while 4/4 patients with endocan_{D0-D7} > +120% died. Regarding patients with endocan_{D0-D7} in the gray zone ranging between -40%

<https://doi.org/10.1016/j.medin.2022.04.003>

0210-5691/© 2022 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

Please cite this article as: C. Levy, N. Dognon, S. Normandin et al., Assessment of plasma endocan for the prediction of mortality in COVID-19 patients undergoing veno-venous ECMO: A pilot study, *Medicina Intensiva*, <https://doi.org/10.1016/j.medin.2022.04.003>

Table 1 Characteristics of patients and biomarkers in survivors and non-survivors.

	Survivors		p value
	Yes (n=5)	No (n=6)	
<i>Demographical data</i>			
Sex, male	4 (80%)	5 (83%)	1
Age, years	48 [33; 62]	57 (48; 63)	0.43
BMI, kg/m ²	37 [32; 40]	34 [28; 42]	0.66
<i>Severity score on ECMO implantation</i>			
SOFA	9 [6; 13]	9 [8; 11]	0.93
RESP	1 [-6; 2.5]	-4 [-6; -2]	0.43
<i>Comorbidities</i>			
Diabetes mellitus	2 (40%)	1 (17%)	0.55
Chronic respiratory failure	0 (0%)	0 (0%)	1
COPD	0 (0%)	2 (33%)	0.45
Coronary disease	1 (20%)	1 (17%)	1
Immunocompromised patients	0 (0%)	0 (0%)	1
<i>Characteristics of ECMO</i>			
Time from onset of symptoms to ECMO, days	21 [10.5; 33.5]	18 [13.5; 24]	0.71
Time from ICU admission to ECMO, days	13 [6; 28]	11 [6; 17]	0.58
Time from invasive MV to ECMO, days	3 [0.5; 20]	9.5 [3; 13]	0.41
Invasive MV initiated on the day of ECMO implantation and maintained for less than 24 h	2 (40%)	0 (0%)	0.18
RPM on day of ECMO implantation, ×1000	3.9 [2.5; 4.6]	3.7 [3.4; 4.1]	0.93
ECMO blood flow on day of ECMO implantation	4.8 [3.9; 7.1]	5.2 [4.6; 6.3]	0.85
<i>Outcomes</i>			
Duration of ECMO, days	18 [12; 34]	27 [19; 33]	0.2
Length of stay in hospital, days	53 [35; 79]	36 [31; 49]	0.31
Length of invasive MV, days	13 [5; 43]	26 [34; 48.5]	0.25
<i>Biomarkers</i>			
Endocan at D0, ng/ml	7.9 [3.8; 12.2]	4.7 [3; 5.7]	0.25
Endocan at D7, ng/ml	4.3 [3.9; 5.6]	12.9 [6.1; 19]	0.017
Variation of endocan between D0 and D7, %	-49 [-65; 52]	208 [-1; 612]	0.03
CRP at D0, mg/l	118 [26; 150]	94 [68; 200]	0.66
CRP at D7, mg/l	39 [35; 123]	68 [50; 77]	0.41
Variation of CRP between D0 and D7, %	4 [-75; 484]	-17 [-72; -5]	0.54
Fibrinogen at D0, g/l	6.1 [3.9; 6.8]	7.1 [4.9; 8.1]	0.33
Fibrinogen at D7, g/l	4.6 [2.7; 5.1]	5.1 [4.3; 5.6]	0.23
Variation of fibrinogen between D0 and D7, %	-28 [-50; 15]	-26 [-43; 9]	1

Data are presented as number (%) or median [IQR]. BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; D0: day of ECMO implantation; D7: day 7 following ECMO implantation; ECMO: Extra Corporeal Membrane Oxygenation; ICU: Intensive Care Unit; MV: Mechanical Ventilation; RESP: Respiratory Extracorporeal Membrane Oxygenation Survival Prediction; RPM: Rounds Per Minute; SOFA: Sequential Organ Failure Assessment; VAP: Ventilator Associated Pneumonia.

and +120%, 2/2 survivors had endocan_{D0} < 5 ng/ml, while 2/2 non-survivors had endocan_{D0} > 5 ng/ml (Fig. 1). These cut-offs were inferred from the CART algorithm, and are not supported by any statistical test.

We hereby report results from a pilot study exploring the potential usefulness of endocan in patients with Covid-19 related ARDS undergoing V-V ECMO. Compared to survivors, non-survivors from our cohort were older, with greater RESP scores and longer time from invasive MV to ECMO implantation, which was in line with previously published data.

Data from this pilot study suggest that among patients undergoing V-V ECMO for COVID-19 related ARDS, survival

on ICU discharge would be associated with significant fall in plasma endocan measured 1 week after ECMO implantation. Indeed, subjects experiencing marked fall in plasma endocan were all discharged alive from ICU, while those with greatest rises did not survive. Further, it seems that patients with intermediate variations of plasma endocan might be segregated into 2 groups according to initial levels of plasma endocan: subjects with baseline values lower than 5 ng/ml who survived, in contrast with those exhibiting initial values higher than 5 ng/ml who were not discharged alive from ICU.

These results are in line with previous data regarding the biological role of endocan in critically ill subjects. Indeed,




Figure 1 Decision tree for prediction of survival on ICU discharge. Endocan_{D0}, endocan_{D7}, endocan_{D0-D7}, CRP_{D0}, CRP_{D7}, CRP_{D0-D7}, fibrinogen_{D0}, fibrinogen_{D7} and fibrinogen_{D0-D7} were tested as covariates for survival in ICU prediction model. D0: day of ECMO implantation. D7: day 7 following ECMO implantation; D0–D7: variation between D0 and D7, calculated as (value on D7 – value on D0)/value on D0.

secretion of endocan is upregulated by pro-inflammatory cytokines,⁷ and endocan has been widely reported as a marker of pulmonary endothelial stress.² Furthermore, endocan is known as an inhibitor of leukocyte recruitment, therefore regulating lung inflammation.⁸ Consistent data suggest that low circulating levels of endocan at the early phase of lung aggression, followed by secondary rise in its plasmatic values, would reflect insufficient initial protection against lung inflammation, being thus associated with poor outcomes.^{5,9–11} Interestingly, both patients from our cohort who underwent ECMO implantation with a duration of invasive MV < 24h experienced marked decreases of plasma endocan on D7, respectively found at –69% and –47%. Further studies are needed to investigate the significance of these results.

Authors' contributions

AT, SA and SBL designed the study. AT wrote the manuscript. FBL, CA, FD and YT contributed to data collection. SA and SBL participated in its critical revision. All authors read and approved the final manuscript.

Funding

None declared.

Conflict of interest

The authors listed on this publication have no conflict of interest.

Acknowledgements

None.

Appendix A. Lille Intensive Care COVID-19 group

Erika Parmentier-Decrucq, Julien Poissy, Sylvain Dubucquoi, Pauline Boddaert, Morgan Caplan, Julien Goutay, Arthur Durand, Benoit Graffin, Myrtille Gaudel, Charles Detolenaere, Ines Gueguen, Marine Van Ceunebroek, Romain Tortuyaux, Ouriel Saura, Ahmed El Kalioubie, Raphael Favory, Patrick Girardie, Marion Houard, Emmanuelle Jaillette, Mercedes Jourdain, Geoffrey Ledoux, Daniel Mathieu, Anne Sophie Moreau, Saad Nseir, Thierry Onimus, Sebastien Preau, Laurent Robriquet, Anahita Rouze, Sophie Six, Jerome Soquet, Valentin Loobuyck, Agnes Mugnier, André Vincentelli.

References

1. Ramanathan K, Shekar K, Ling RR, Barbaro RP, Wong SN, Tan CS, et al. Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. *Crit Care Lond Engl.* 2021;25:211.
2. De Freitas Caires N, Gaudet A, Portier L, Tsicopoulos A, Mathieu D, Lassalle P. Endocan, sepsis, pneumonia, and acute respiratory distress syndrome. *Crit Care Lond Engl.* 2018;22:280.
3. Pascreau T, Tcherakian C, Zuber B, Farfour E, Vasse M, Lassalle P. A high blood endocan profile during COVID-19 distinguishes moderate from severe acute respiratory distress syndrome. *Crit Care Lond Engl.* 2021;25:166.
4. Tang L, Zhao Y, Wang D, Deng W, Li C, Li Q, et al. Endocan levels in peripheral blood predict outcomes of acute respiratory distress syndrome. *Mediators Inflamm.* 2014;2014:625180.
5. Orbegozo D, Rahmania L, Irazabal M, Mendoza M, Annoni F, De Backer D, et al. Endocan as an early biomarker of severity in patients with acute respiratory distress syndrome. *Ann Intensive Care.* 2017;7:93.
6. Tsangaris I, Tsantes A, Vrigkou E, Kopterides P, Pelekanou A, Zerva K, et al. Angiopoietin-2 levels as predictors of outcome in

- mechanically ventilated patients with acute respiratory distress syndrome. *Dis Markers*. 2017;2017:6758721.
7. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. *J Biol Chem*. 1996;271:20458–64.
 8. Gaudet A, Portier L, Prin M, Copin M-C, Tscopoulos A, Mathieu D, et al. Endocan regulates acute lung inflammation through control of leukocyte diapedesis. *J Appl Physiol Bethesda Md* 1985. 2019;127:668–78.
 9. Gaudet A, Parmentier E, Dubucquoi S, Poissy J, Duburcq T, Lassalle P, et al. Low endocan levels are predictive of Acute Respiratory Distress Syndrome in severe sepsis and septic shock. *J Crit Care*. 2018;47:121–6.
 10. Ioakeimidou A, Pagalou E, Kontogiorgi M, Antoniadou E, Kaziani K, Psaroulis K, et al. Increase of circulating endocan over sepsis follow-up is associated with progression into organ dysfunction. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol*. 2017.
 11. Gaudet A, Parmentier E, Dubucquoi S, Poissy J, Duburcq T, Portier L, et al. The complex kinetics of blood endocan during the time course of sepsis and acute respiratory distress syndrome. *Crit Care Lond Engl*. 2019;23: 86.

C. Levy^{a,b,c,e}, N. Dognon^{a,b,c,e}, S. Normandin^{a,b,c,e},
T. Duburcq^{a,b,c,e}, A. Gaudet^{a,b,c,d,e,*},
Lille Intensive Care COVID-19 group¹

^a *Department of Intensive Care Medicine, Critical Care Center, CHU Lille, F-59000 Lille, France*

^b *University of Lille, U995-LIRIC-Lille Inflammation Research International Center, Lille, France*

^c *CHU Lille, Immunology Institute, F-59000 Lille, France*

^d *University Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR9017-CIIL-Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France*

^e *University Lille, Inserm, U1285, CNRS, UMR 8576 - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France*

* Corresponding author.

E-mail address: alexandre.gaudet@chru-lille.fr
(A. Gaudet).